Integrated Oncology Learning - Activity Details
To begin this acvivity, please choose a participation option at the bottom of this page.
Online Grand Rounds:
Chemotherapy Options in Metastatic Breast Cancer: Combination Strategies
Release Date: August 7, 2009
Expiration Date: August 7, 2010
Lecture Overview
The primary goals of therapy for patients with metastatic breast cancer are to extend survival and relieve symptoms. In patients with HER2– breast cancer, systemic chemotherapy remains the foundation of treatment, but no single optimal regimen has emerged. Ongoing efforts to improve outcomes in these patients are focusing on the combination of active cytotoxic agents with a variety of newer therapeutic agents. The combination of antiangiogenic agents with cytotoxic chemotherapies, including taxanes, anthracyclines, and antimetabolites, has resulted in improved efficacy in patients with advanced breast cancer. Combinations of antimetabolites and microtubule-targeting agents, such as taxanes or epothilones, have demonstrated efficacy in both first- and second-line settings in these patients. Recent insights into the molecular biology of estrogen receptor–negative/progesterone receptor–negative/HER2– breast cancer (“triple-negative” breast cancer) have led to the development of targeted DNA repair inhibitors that have shown promising efficacy and safety results when added to DNA-damaging cytotoxic therapy in patients with metastatic disease.
The purpose of this activity is to update physicians on the latest efficacy and safety data on novel combination therapies in the treatment of patients with HER2– locally advanced/metastatic breast cancer.
Presented by Physicians’ Education Resource in conjunction with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
This educational activity is directed toward medical oncologists and other specialists practicing in the community or academic setting who are interested in the treatment of breast cancer. Physicians involved in the long-term management of cancer patients as well as fellows, oncology physician assistants, oncology nurses, research nurses, and others with an interest in the treatment of patients with breast cancer are also invited to participate.
Upon completion of this educational activity, you should be able to:
- Evaluate the efficacy and safety of combination regimens that include antiangiogenic and cytotoxic agents as first-line therapy for patients with HER2– locally recurrent/metastatic breast cancer
- Assess clinical data on novel cytotoxic combination regimens for patients with locally advanced/metastatic breast cancer
- Summarize data on the combination of targeted and cytotoxic therapies for patients with metastatic triple-negative breast cancer
Instructions for Participation
- Read the following information before entering the educational activity.
- Complete the Pretest.
- View the Flash video presentation and slides.
- Complete the Posttest.
- Answer the evaluation questions.
- After completion of the Pretest and successful completion of the Posttest and evaluation, you will receive your certificate online.
You will be permitted 2 attempts to successfully complete the Posttest.
You will be asked to login
or create an account.